A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients

2025/05/22 by William R. Mulley, Dhakshayini Tharmaraj, Kevan R. Polkinghorne +16 · 1 voice · 2 citations
Medicine · #Renal Transplantation Outcomes and Treatments #Transplantation: Methods and Outcomes #Xenotransplantation and immune response

paper · doi:10.1016/j.kint.2025.04.023

openalex publication_date 2025/05/22 · crossref created 2025/05/22 · crossref issued 2025/09/01 · crossref published 2025/09/01 · crossref published-print 2025/09/01 · openalex created_date 2025/10/10 · crossref deposited 2025/11/04 · crossref indexed 2026/07/09 · openalex updated_date 2026/07/22

Citations

• A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection

Cited by

• Intravenous immunoglobulin for chronic active antibody-mediated rejection: a signal of hope in an evolving field
• Adopting a wider view: factoring blood, biopsy, and urine into kidney transplant outcomes

Discussions

• A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients doi.org/10.1016/j.kint. [bsky, 5 points, 0 comments]